Key statistics dashboard for Organon & Co. (OGN). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio).
Stock Data
| Price | $13.67 |
| Market Cap | $3.6B |
| Enterprise Value | $11.01B |
| Beta | 0.64 |
| Exchange | NYSE |
| Country | US |
Valuation Multiples
| P/E Ratio | 17.30 |
| Price / Book | 3.57 |
| P/S | 0.59 |
| EV/EBITDA | 8.43 |
| EV/Sales | 1.80 |
| EV/FCF | 22.11 |
| P/FCF | 7.21 |
| Earnings Yield | 5.82% |
| FCF Yield | 13.87% |
| Dividend Yield | 0.59% |
Profitability
| Gross Margin | 52.98% |
| EBIT Margin | 15.65% |
| EBITDA Margin | 21.32% |
| Operating Margin | 19.29% |
| Net Margin | 3.41% |
| Return on Equity | 23.44% |
| Return on Assets | 1.59% |
| Return on Invested Capital | 4.73% |
| Return on Capital Employed | 11.19% |
Financial Health
| Current Ratio | 1.95 |
| Quick Ratio | 1.44 |
| Cash Ratio | 0.43 |
| Debt / Equity | 8.50 |
| Debt / Assets | 64.90% |
| Net Debt / EBITDA | 5.68 |
| Interest Coverage | 2.53 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 1.21 |
Per-Share Data
| Revenue per share | 23.33 |
| Book Value per share | 3.83 |
| Cash per share | 4.31 |
| FCF per share | 1.90 |
| Tangible Book Value per share | -16.22 |
| Dividend per share | 0.08 |
Related companies: ALVO · AUPH · AVDL · GRDN · HRMY · MD · NUVB
Explore sector: Healthcare · Drug Manufacturers - General
More sections of OGN: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks